BR112013023914A2 - derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio - Google Patents

derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio

Info

Publication number
BR112013023914A2
BR112013023914A2 BR112013023914A BR112013023914A BR112013023914A2 BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2 BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A BR112013023914 A BR 112013023914A BR 112013023914 A2 BR112013023914 A2 BR 112013023914A2
Authority
BR
Brazil
Prior art keywords
oxazine
receptor modulators
benzo derivatives
calcium sensor
sensor receptor
Prior art date
Application number
BR112013023914A
Other languages
English (en)
Portuguese (pt)
Inventor
Chetan Sanjay Pawar
Ganesh Navinchandra Gote
Mahadeo Bhaskar Tryambake
Majid Bashir Sayyed
Manojkumar Ramprasad Shukla
Pachpute Dilip Vipul
Rajender Kumar Kamboj
Sanjeev Anant Kulkarni
Sarde Gangaram Ankush
Venkata P Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112013023914A2 publication Critical patent/BR112013023914A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112013023914A 2011-03-18 2012-03-16 derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio BR112013023914A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
BR112013023914A2 true BR112013023914A2 (pt) 2016-12-13

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013023914A BR112013023914A2 (pt) 2011-03-18 2012-03-16 derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio

Country Status (16)

Country Link
US (1) US9464063B2 (enExample)
EP (1) EP2686306B1 (enExample)
JP (1) JP6033835B2 (enExample)
KR (1) KR20140051846A (enExample)
CN (1) CN103459377B (enExample)
AP (1) AP2013007153A0 (enExample)
AU (1) AU2012232706B2 (enExample)
BR (1) BR112013023914A2 (enExample)
CA (1) CA2829466A1 (enExample)
EA (1) EA024893B9 (enExample)
IL (1) IL228461A0 (enExample)
MX (1) MX2013010670A (enExample)
PH (1) PH12013501899A1 (enExample)
SG (1) SG193331A1 (enExample)
WO (2) WO2012127388A1 (enExample)
ZA (1) ZA201306837B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24325B1 (es) 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
WO2014033604A1 (en) 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
CA2920818A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
BR112022012663A2 (pt) 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
FI4090654T3 (fi) 2020-01-17 2025-09-30 Lupin Ltd Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3,4-二氢-2h-1,4-苯并噁嗪衍生物、制备及其应用
FR2809396B1 (fr) * 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 CaSRアンタゴニスト
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
US7585886B2 (en) * 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008057282A1 (en) * 2006-10-26 2008-05-15 Amgen Inc. Calcium receptor modulating agents
JPWO2008059854A1 (ja) * 2006-11-16 2010-03-04 アステラス製薬株式会社 ピペリジン誘導体またはその塩
CA2706076A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
CN103980309B (zh) 2008-10-03 2016-04-06 味之素株式会社 CaSR激动剂
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Egr装置及びこれを備えたエンジン装置
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Also Published As

Publication number Publication date
EP2686306B1 (en) 2017-01-04
JP2014510097A (ja) 2014-04-24
US9464063B2 (en) 2016-10-11
AP2013007153A0 (en) 2013-09-30
SG193331A1 (en) 2013-10-30
CN103459377B (zh) 2016-09-07
CA2829466A1 (en) 2012-09-27
ZA201306837B (en) 2015-05-27
JP6033835B2 (ja) 2016-11-30
EP2686306A1 (en) 2014-01-22
AU2012232706A1 (en) 2013-09-26
WO2012127385A1 (en) 2012-09-27
EA201370205A1 (ru) 2014-01-30
PH12013501899A1 (en) 2013-11-25
WO2012127388A1 (en) 2012-09-27
CN103459377A (zh) 2013-12-18
US20140018358A1 (en) 2014-01-16
NZ616676A (en) 2015-09-25
EA024893B9 (ru) 2017-01-30
AU2012232706B2 (en) 2016-12-15
EA024893B1 (ru) 2016-10-31
IL228461A0 (en) 2013-12-31
MX2013010670A (es) 2013-12-06
KR20140051846A (ko) 2014-05-02

Similar Documents

Publication Publication Date Title
BR112013023914A2 (pt) derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio
BR112013002871A2 (pt) derivados de isoxazolina como agentes antiparasitários
BR112013023068A2 (pt) derivados de isoxazolina espirocíclica como agentes antiparasíticos
CU24152B1 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
LT3093291T (lt) Dipakeistieji oktahidropirolo [3,4-c]pirolai, kaip oreksino receptoriaus moduliatoriai
BR112013015234A2 (pt) derivados fosforosos como moduladores de receptor de quimiocina
PT2528897E (pt) Derivados de piridina dissubstituída como anticancerígenos
BR112012028519A2 (pt) compostos de 2,5,6,7-tetrahidro-[1,4]oxazepin-3-ilamina ou 2,3,6,7-tetrahidro-[1,4]oxazepin-5-ilamina
BRPI1013766A2 (pt) "derivados de isoxazol-piridina como moduladores de gaba"
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
EP2826921A4 (en) CONSTRUCTION MACHINE
BR112012018401A2 (pt) sensor de posição rotativo
BRPI1009200A2 (pt) derivados de benzo tiadiazepinas como moduladores dos receptores ampa e nmda
BRPI0910607A2 (pt) derivados do ciclohexano espirocíclicos substituídos
EP2865812A4 (en) CONSTRUCTION MACHINE
CR20130403A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
ZA201306576B (en) Substituted morpholines as modulators for the calcium sensing receptor
EP2803830A4 (en) Construction machine
BR112013021602A2 (pt) derivados de heteroarila como moduladores de nachr alfa7.
CO6890111A2 (es) Derivados de isoxazolina como compuestos insecticidas
CO6811856A2 (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
EP2808519A4 (en) CONSTRUCTION MACHINE
EP2557237A4 (en) CONSTRUCTION MACHINE
BRPI1009428A2 (pt) 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
EP2803832A4 (en) CONSTRUCTION MACHINE

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: LUPIN LIMITED (IN)

B25B Requested transfer of rights rejected

Owner name: LUPIN LIMITED (IN)

B25I Requirement for requested change of headquarter

Owner name: LUPIN LIMITED (IN)

Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 870160061657 DE 21/10/2016, E NECESSARIO APRESENTAR DOCUMENTACAO PARA QUE O INTERESSADO SEJA O TITULAR DO PEDIDO.

B25H Request for change of headquarter rejected

Owner name: LUPIN LIMITED (IN)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 87016061657 DE 21/10/2016,POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2486, DE 28/08/2018.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI